rb 6145 has been researched along with Experimental Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adams, GE; Cole, S; Fielden, EM; Jenkins, TC; Naylor, MA; O'Neill, P; Stier, MA; Stratford, IJ; Suto, MJ; Threadgill, MD | 1 |
| Bremner, JC | 1 |
| Adams, GE; Butler, SA; Cole, S; Stratford, IJ; Williams, C; Wood, PJ | 1 |
| Adams, GE; Bremner, JC; Cole, S; Edwards, HS; Stratford, IJ | 1 |
1 review(s) available for rb 6145 and Experimental Neoplasms
| Article | Year |
|---|---|
Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Line; Cell Survival; Humans; Misonidazole; Neoplasms, Experimental; Nitroimidazoles; Oxidation-Reduction; Prodrugs; Radiation-Sensitizing Agents | 1993 |
3 other study(ies) available for rb 6145 and Experimental Neoplasms
| Article | Year |
|---|---|
Synthesis and evaluation of alpha-[[(2-haloethyl)amino]methyl]-2- nitro-1H-imidazole-1-ethanols as prodrugs of alpha-[(1-aziridinyl)methyl]-2- nitro-1H-imidazole-1-ethanol (RSU-1069) and its analogues which are radiosensitizers and bioreductively activate
Topics: Animals; Antineoplastic Agents; Chemical Phenomena; Chemistry; Cytotoxins; Mice; Mice, Inbred C3H; Misonidazole; Neoplasms, Experimental; Prodrugs; Radiation-Sensitizing Agents | 1990 |
Enhancement of bioreductive drug toxicity in murine tumours by inhibition of the activity of nitric oxide synthase.
Topics: Animals; Antineoplastic Agents; Cell Hypoxia; Cell Survival; Drug Synergism; Enzyme Inhibitors; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Nitric Oxide Synthase; Nitroarginine; Nitroimidazoles | 1997 |
Bioreductive drugs as post-irradiation sensitizers: comparison of dual function agents with SR 4233 and the mitomycin C analogue EO9.
Topics: Animals; Antineoplastic Agents; Aziridines; Cell Hypoxia; Cell Survival; Combined Modality Therapy; Dose-Response Relationship, Drug; Indolequinones; Indoles; Mice; Mice, Inbred C3H; Misonidazole; Neoplasm Transplantation; Neoplasms, Experimental; Nitroimidazoles; Prodrugs; Tirapazamine; Triazines | 1992 |